Phenotype-Specific Mortality Outcomes with Dipeptidyl Peptidase-4 Inhibitors in Heart Failure and Diabetes: Real-World Evidence from a Retrospective Single-Center Cohort Study.

J Clin Med · 2026 · PMC13117671 · PMID 42074955

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

CV Mortality Outcomes In the unweighted analyses, use of DPP-4 inhibitors was associated with numerically lower CV mortality across all HF phenotypes, although these differences did not reach statistical significance for patients with HFpEF or HFrEF.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.